Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  17:414-423. 2019
2019 Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia.Case Reports in Hematology.  2019:3536517. 2019
2018 Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  16:1500-1537. 2018
2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
2018 Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseLeukemia & Lymphoma.  59:363-371. 2018
2017 Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  15:1193-1207. 2017
2016 Recent advances and novel treatment paradigms in acute lymphocytic leukemia.Therapeutic Advances in Hematology.  7:252-269. 2016
2016 Lysyl oxidase is associated with increased thrombosis and platelet reactivityBlood.  127:1493-1501. 2016
2015 Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemiaFuture Oncology.  11:1729-1739. 2015
2013 Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptideCell Cycle.  12:1242-1250. 2013
2012 Megakaryocyte pathology and bone marrow fibrosis: The lysyl oxidase connectionBlood.  120:1774-1781. 2012
2011 Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidaseJournal of Biological Chemistry.  286:27630-27638. 2011
2010 New roles for cyclin E in megakaryocytic polyploidizationJournal of Biological Chemistry.  285:18909-18917. 2010
2008 Direct visualization of the endomitotic cell cycle in living megakaryocytes: Differential patterns in low and high ploidy cellsCell Cycle.  7:2352-2356. 2008
2008 Survivin overexpression alone does not alter megakaryocyte ploidy nor interfere with erythroid/megakaryocytic lineage development in transgenic miceBlood.  111:4092-4095. 2008
2007 Transforming growth factor-beta1 affects interleukin-10 production in the bone marrow of patients with chronic idiopathic neutropeniaEuropean Journal of Haematology.  79:531-538. 2007

Chapter

Year Title Altmetric
2016 Immune-mediated thrombocytopenia.  209-220. 2016
2009 Development of megakaryocytes.  95-126. 2009

Principal Investigator On

  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by ABBVIE INC 2018 - 2023
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD 2019 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2022
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2019 - 2022
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2021
  • Investigator On

  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2023
  • UAB 1640-Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2017 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2021
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2018 - 2021
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by AGIOS 2017 - 2020
  • Private Grant  awarded by ABLYNX NV 2016 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2018 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2019
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2016 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2018
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2018
  • Private Grant  awarded by AMGEN, INC. 2014 - 2018
  • Private Grant  awarded by Janssen 2016 - 2017
  • Private Grant  awarded by AGIOS 2015 - 2017
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2017
  • Education And Training

  • Doctor of Philosophy in Hematology Residency Program, University of Crete 2013
  • Master of Science in Biological and Biomedical Sciences, University of Crete 2007
  • Doctor of Medicine, University of Crete 2005
  • Bachelor of Science or Mathematics in Molecular Biology, The University of Glasgow 1999
  • Jacobi Medical / Albert Eistein College of Medicine, Residency 2013
  • Cleveland Clinic Foundation, Postdoctoral Fellowship 2016
  • Full Name

  • Nikolaos Papadantonakis